London‑listed PRTech firm Pathos Communications has developed its proprietary AI platform, PathosMind. Designed exclusively for use by Pathos employees and partners, it surfaces stories that genuinely ...
Developed by London Stock Exchange–listed MediaTech firm Pathos Communications, PathosMind is a proprietary AI platform designed to surface stories that truly resonate with audiences. By scanning more ...
In another signal of the appetite among investors for companies applying artificial intelligence to drug discovery, Pathos AI has gathered an impressive $365 million in fourth-round financing as it ...
2025 was a very good year for my favorite genre.
There was an error while loading. Please reload this page.
There was an error while loading. Please reload this page.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback